Infographic | January 13, 2023

Next-Generation DMSO-Free & Serum-Free Cryopreservation For Cell And Gene Therapy

Source: X-Therma

By Mark Kline, Ph.D.1, Arthi Shridhar, Ph.D.1,Steve Oh, Ph.D.2, Alan Lam, Ph.D.2, and Simon Cool, Ph.D.2, Renata Gilfanova, Ph.D.3,Philip Norris, Ph.D.3,Marcus Muench, Ph.D.3,Todd McDevitt, Ph.D.4,Xiaoxi Wei, Ph.D.1 X-Therma Inc., Berkeley1; Agency for Science, Technology and Research, Singapore2; Vitalant Research Institute, San Francisco3. Gladstone Institutes, San Francisco4


Existing standards in cryopreservation use 5-10% dimethyl sulfoxide (DMSO) and often serum. These products have not been significantly improved for over 50 years. DMSO exhibits acute toxicity in patients and causes adverse cell mutation at low levels (0.1%) including irreversible cell chromosome damage and alterations in the epigenetic landscape. Serum remains a black box, inherently introducing batch-to-batch variability, diminished clinical reproducibility, and compromised precision in therapeutic delivery. However, performance in available DMSO & serum-free solutions is often compromised, warranting urgent advancement.

Learn about XT-Thrive®, a completely defined, non-toxic cryopreservation solution for cell & gene therapy and cell banking applications at ultra-low temperatures (-70°Cto-196°C). Formulated without any DMSO, serum, or recombinant proteins, every component is fully identified and quantified for superior compatibility with cGMP manufacturing processes.

access the Infographic!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Cell & Gene